Total ginsenosides synergize with ulinastatin against septic acute lung injury and acute respiratory distress syndrome.
Total ginsenosides synergize with ulinastatin (UTI) against septic acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). We randomly divided 80 cases of severe sepsis-induced ALI and ARDS into a UTI group and a ginsenosides (GS)+UTI group. Continuous electrocardiac monitoring of pulse, respiratory rate, blood pressure, and heart rate; invasive hemodynamic monitoring; ventilator-assisted breathing and circulation support; and anti-infection as well as UTI treatment were given in the UTI group with GS treatment added for 7 consecutive days in the GS+UTI group. The indicators of pulmonary vascular permeability, pulmonary circulation, blood gases, and hemodynamics as well as APACHE II and ALI scores were detected on days 1, 3, and 7. The ALI score in the GS+UTI group was significantly decreased (P < 0.05) compared with that of the UTI group, and the indicators of pulmonary capillary permeability such as pulmonary vascular permeability index, extravascular lung water index, and oxygenation index, in the GS+UTI group improved significantly more than that of the UTI group. The indicators of hemodynamics and pulmonary circulation such as cardiac index, intrathoracic blood volume index, and central venous pressure improved significantly (P < 0.05), and the APACHE II score in the GS+UTI group was lower than that of the UTI group. GS can effectively collaborate with UTI against ALI and/or ARDS.
Department of Emergency, General Hospital of PLA Beijing 100853, China.
Rongju
R
Sun
Department of Emergency or Respiration, No. 2 Hospital Affiliated to Traditional Chinese Medicine College of Guiyang Guiyang 550003, China.
Yana
Y
Li
Department of Emergency, General Hospital of PLA Beijing 100853, China.
Wei
W
Chen
Department of Emergency, General Hospital of PLA Beijing 100853, China.
Fei
F
Zhang
Department of Emergency, General Hospital of PLA Beijing 100853, China.
Tanshi
T
Li
D055371:Acute Lung Injury / Q000188:drug therapy* / Q000209:etiology; D000293:Adolescent; D000328:Adult; D000368:Aged; D004357:Drug Synergism; D005260:Female; D036145:Ginsenosides / Q000008:administration & dosage*; D006023:Glycoproteins / Q000008:administration & dosage*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000209:etiology; D018805:Sepsis / Q000150:complications; D014361:Trypsin Inhibitors / Q000008:administration & dosage; D055815:Young Adult
D036145:Ginsenosides; D006023:Glycoproteins; D014361:Trypsin Inhibitors; C028665:urinastatin
ALI; ARDS; Ulinastatin; ginsenoside; sepsis; systemic inflammatory response syndrome